Subclinical atherosclerosis and brain health in midlife: Rationale and design of the PESA-Brain study
Study context
- Population
- Asymptomatic middle-aged individuals (40–54 years) in the Progression of Early Subclinical Atherosclerosis (PESA) cohort, Madrid (Spain)target
- Participants
- 1,000 individuals
- Primary endpoint
- Structural, functional and vascular brain alterations, amyloid burden and subtle cognitive impairment associated with CV risk factors and subclinical atherosclerosis (hypothesis)
- Follow-up
- 10-year PESA visit
Methodological detailsprospective observational cohort study, longitudinal, single city (Madrid, Spain), 10-year follow-up visit, Started October 2020; estimated completion December 2024, Neuropsychological testing, multimodal neuroimaging and blood-based neuropathological biomarkers
- Prospective observational cohort study
- Longitudinal
- Single city (Madrid, Spain)
- 10-year follow-up visit
- Started October 2020; estimated completion December 2024
- Neuropsychological testing, multimodal neuroimaging and blood-based neuropathological biomarkers
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Subclinical atherosclerosis and brain health in midlife: Rationale and design of the PESA-Brain study. Am Heart J. Published 24 September 2024. doi:10.
Summarised from the published abstract; every number is checked against it